Patients with mastocytosis mostly had similar rates of atopy and allergies as the general population, except for certain conditions such as asthma. While patients with mastocytosis (both systemic [SM] ...
ADI-001 therapy demonstrated a strong safety profile with low rates of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Researchers have developed a novel T-cell ...
Mepolizumab is a new therapeutic that holds potential in improving clinical outcomes in EGPA both safety and effectively. Researchers found that mepolizumab is useful in aiding disease control in ...
Dr. Vishnevetsky is heading a groundbreaking clinical trial of the cannabinoid spray nabiximols for treating the symptoms of NMOSD. Larry Luxner, senior correspondent for Rare Disease Advisor, ...
Closeup of cannabis leaves and flowers at the Curio Wellness grow facility in Timonium, Maryland (Photo by Larry Luxner) Massachusetts General Hospital is formalizing federal approvals to test a ...
IgG4-RD of the breast is rare but should be considered a differential diagnosis if biopsies rule out cancer. Immunoglobulin G4-related disease of the breast (IgG4-BD) is rare but should be considered ...
Which of the statements below about the facts of hemolytic disease of the fetus and newborn (HDFN) are correct? Select one of the options for each question, then submit your answers to see how well ...
Specific biology therapy can be quite effective in patients with indolent SM. A young woman with indolent systemic mastocytosis (ISM), a subtype of systemic mastocytosis (SM), and concurrent ...
Hereditary transthyretin (TTR) amyloidosis due to the T60A mutation in the TTR gene in Ireland typically presents in the 7th decade of life with already manifest neuropathy well before a cardiac ...
Avapritinib, a selective KIT mutation-targeted tyrosine kinase inhibitor, has already been approved in the US and Europe for the treatment of adults with indolent SM. A recent analysis of PIONEER data ...
Results showed that patients on efgartigimod had evidence of clinical improvement and a decreased risk of relapse compared to those on placebo. Patients with chronic inflammatory demyelinating ...
Once I had finally been diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP), things moved quickly. I saw my neurologist to get the results of my nerve conduction study on a ...